Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,530 | 236 | 1,279 |
| Samples | 741 | 144 | 589 |
| Peptides | 517 | 91 | 449 |
Function
ATP1A2 · ATPase Na+/K+ transporting subunit alpha 2
The protein encoded by this gene belongs to the family of P-type cation transport ATPases, and to the subfamily of Na+/K+ -ATPases. Na+/K+ -ATPase is an integral membrane protein responsible for establishing and maintaining the electrochemical gradients of Na and K ions across the plasma membrane. These gradients are essential for osmoregulation, for sodium-coupled transport of a variety of organic and inorganic molecules, and for electrical excitability of nerve and muscle. This enzyme is composed of two subunits, a large catalytic subunit (alpha) and a smaller glycoprotein subunit (beta). The catalytic subunit of Na+/K+ -ATPase is encoded by multiple genes. This gene encodes an alpha 2 subunit. Mutations in this gene result in familial basilar or hemiplegic migraines, and in a rare syndrome known as alternating hemiplegia of childhood. [provided by RefSeq, Oct 2008].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 503 amino-acid changes on canonical ENST00000361216 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in ATP1A2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in ATP1A2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 8/40 20% | 0/0 0% |
| Endometrial Carcinoma | 11/42 26% | 32/612 5% |
| Melanoma | 19/210 9% | 85/1899 4% |
| Squamous Cell Lung Carcinoma | 6/57 11% | 22/810 3% |
| Non-Small Cell Lung Carcinoma | 14/304 5% | 40/1390 3% |
| Colorectal Carcinoma | 16/143 11% | 84/3239 3% |
| Other Solid Cancers | 3/94 3% | 40/1515 3% |
| Neuroendocrine Tumour | 16/154 10% | 2/577 0% |
| Cervical Carcinoma | 4/35 11% | 7/422 2% |
| Gastric Carcinoma | 1/74 1% | 44/1809 2% |
| Esophageal Carcinoma | 0/23 0% | 18/769 2% |
| Other Sarcomas | 3/69 4% | 12/699 2% |
| Bladder Carcinoma | 1/58 2% | 15/956 2% |
| Ovarian Carcinoma | 7/109 6% | 9/998 1% |
| Hodgkins Lymphoma | 1/16 6% | 1/122 1% |
| Head and Neck Carcinoma | 6/85 7% | 16/1574 1% |
| Glioma | 1/52 2% | 26/2127 1% |
| Ewings Sarcoma | 0/63 0% | 4/262 2% |
| Small Cell Lung Carcinoma | 0/9 0% | 9/752 1% |
| Pancreatic Carcinoma | 4/89 4% | 15/1611 1% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Germ Cell Tumour | 0/25 0% | 2/169 1% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 22/2550 1% |
| Hepatocellular Carcinoma | 3/46 7% | 16/2210 1% |
| Kidney Carcinoma | 0/85 0% | 12/1862 1% |
| Biliary Tract Carcinoma | 2/54 4% | 4/950 0% |
| Plasma Cell Myeloma | 1/44 2% | 1/305 0% |
| Neuroblastoma | 5/87 6% | 3/1331 0% |
| Breast Carcinoma | 1/144 1% | 18/3264 1% |
| B-Cell Non-Hodgkins Lymphoma | 3/88 3% | 11/2534 0% |
Mutation Distribution
Where ATP1A2 is mutated · all tissues, split by cell line vs tissue
How many mutations in ATP1A2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,530 mutations in ATP1A2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|